ATE283069T1 - Melanomzellinien, welche immundominante melanomantigene teilen und verfahren zu deren anwendung - Google Patents

Melanomzellinien, welche immundominante melanomantigene teilen und verfahren zu deren anwendung

Info

Publication number
ATE283069T1
ATE283069T1 AT97936164T AT97936164T ATE283069T1 AT E283069 T1 ATE283069 T1 AT E283069T1 AT 97936164 T AT97936164 T AT 97936164T AT 97936164 T AT97936164 T AT 97936164T AT E283069 T1 ATE283069 T1 AT E283069T1
Authority
AT
Austria
Prior art keywords
melanoma
cell line
immunominant
share
cell lines
Prior art date
Application number
AT97936164T
Other languages
German (de)
English (en)
Inventor
Drew M Pardoll
Elizabeth M Jaffee
Adam Adler
Suzanne L Topalian
Steven A Rosenberg
Original Assignee
Univ Johns Hopkins Med
Usa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Johns Hopkins Med, Usa filed Critical Univ Johns Hopkins Med
Application granted granted Critical
Publication of ATE283069T1 publication Critical patent/ATE283069T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT97936164T 1996-08-16 1997-08-04 Melanomzellinien, welche immundominante melanomantigene teilen und verfahren zu deren anwendung ATE283069T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2409896P 1996-08-16 1996-08-16
PCT/US1997/012868 WO1998006746A2 (en) 1996-08-16 1997-08-04 Melanoma cell lines expressing shared immunodominant melanoma antigens and methods of using same

Publications (1)

Publication Number Publication Date
ATE283069T1 true ATE283069T1 (de) 2004-12-15

Family

ID=21818860

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97936164T ATE283069T1 (de) 1996-08-16 1997-08-04 Melanomzellinien, welche immundominante melanomantigene teilen und verfahren zu deren anwendung

Country Status (8)

Country Link
US (1) US6187306B1 (enExample)
EP (1) EP0929318B1 (enExample)
JP (5) JP2001517206A (enExample)
AT (1) ATE283069T1 (enExample)
AU (1) AU3889997A (enExample)
CA (1) CA2263503C (enExample)
DE (1) DE69731756T2 (enExample)
WO (1) WO1998006746A2 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096313A (en) * 1996-02-09 2000-08-01 Ludwig Institute For Cancer Research Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant
US6277368B1 (en) 1996-07-25 2001-08-21 The Regents Of The University Of California Cancer immunotherapy using autologous tumor cells combined with cells expressing a membrane cytokine
US5891432A (en) * 1997-07-29 1999-04-06 The Immune Response Corporation Membrane-bound cytokine compositions comprising GM=CSF and methods of modulating an immune response using same
EP1069917A4 (en) * 1998-03-20 2005-02-09 Genzyme Corp NEW COMPLEMENTARY PAIRS OF RECEPTORS / LIGANDS AND ADOPTIVE IMMUNOTHERAPY USING THE SAME
GB9810040D0 (en) 1998-05-11 1998-07-08 Univ Nottingham Blood borne tumour markers
US6316420B1 (en) * 1998-07-28 2001-11-13 Technion Research And Development Foundation Ltd. DNA cytokine vaccines and use of same for protective immunity against multiple sclerosis
GB9827228D0 (en) * 1998-12-10 1999-02-03 Univ Nottingham Cancer detection method and reagents
DE19905501B4 (de) 1999-02-10 2005-05-19 MediGene AG, Gesellschaft für molekularbiologische Kardiologie und Onkologie Verfahren zur Herstellung eines rekombinanten Adeno-assoziierten Virus, geeignete Mittel hierzu sowie Verwendung zur Herstellung eines Arzneimittels
US20030232399A1 (en) * 2000-06-14 2003-12-18 Robertson John Forsyth Russell Cancer detection methods and reagents
US6541250B2 (en) 2000-06-22 2003-04-01 Aventis Pasteur Limited Continuous adherent melanocyte cell line
US20050201993A1 (en) * 2002-10-09 2005-09-15 Link Charles J.Jr. Antitumor vaccination using allogeneic tumor cells expressing alpha (1,3)-galactosyltransferase
CN104911210A (zh) * 2002-10-09 2015-09-16 衣阿华中央卫生系统 使用表达α(1,3)-半乳糖基转移酶的同种异型肿瘤细胞的抗肿瘤免疫
GB2424273B (en) * 2002-11-14 2007-06-27 Univ Nottingham Method for preparing tumour marker protein
US20050136035A1 (en) * 2003-06-03 2005-06-23 Derek Ko Cell specific replication-competent viral vectors comprising a self processing peptide cleavage site
CA2526120A1 (en) * 2003-06-03 2005-02-24 Cell Genesys, Inc. Compositions and methods for enhanced expression of recombinant polypeptides from a single vector using a peptide cleavage site
US20050186178A1 (en) * 2003-08-28 2005-08-25 Ennist David L. Oncolytic adenoviral vectors encoding GM-CSF
GB2426581A (en) * 2005-05-27 2006-11-29 Univ Nottingham Immunoassay methods
RU2636532C2 (ru) 2005-05-27 2017-11-23 Онкиммьюн Лимитед Улучшенные способы иммуноанализа
JP6092497B2 (ja) 2006-03-30 2017-03-08 ユニバーシティー オブ カリフォルニア 抗ｃｔｌａ−４抗体の限局性分泌のための方法および組成物
US7919079B2 (en) 2006-03-31 2011-04-05 Biosante Pharmaceuticals, Inc. Cancer immunotherapy compositions and methods of use
CN101632020B (zh) 2006-09-13 2013-11-27 昂西免疫有限公司 改进的免疫测定方法
US7998486B2 (en) 2006-10-25 2011-08-16 Newlink Genetics Corporation Enhanced immunogenicity of tumor associated antigens by addition of alphaGal epitopes
AR060424A1 (es) * 2007-04-11 2008-06-18 Consejo Nac Invest Cient Tec Lineas celulares , composiciones para el tratamiento de melanomas que las comprenden procedimientos para preparar las composiciones y metodos de tratamiento
GB0725239D0 (en) * 2007-12-24 2008-02-06 Oncimmune Ltd Calibrator for autoantibody assay
CN102666663A (zh) * 2009-10-23 2012-09-12 道康宁东丽株式会社 新的有机聚硅氧烷共聚物
WO2017023803A1 (en) 2015-07-31 2017-02-09 Regents Of The University Of Minnesota Modified cells and methods of therapy
CA3041068A1 (en) 2016-10-18 2018-04-26 Regents Of The University Of Minnesota Tumor infiltrating lymphocytes and methods of therapy
AU2017363256B2 (en) 2016-11-22 2024-04-18 Alloplex Biotherapeutics Allogeneic tumor cell vaccine
JP2020530307A (ja) 2017-06-30 2020-10-22 インティマ・バイオサイエンス，インコーポレーテッド 遺伝子治療のためのアデノ随伴ウイルスベクター

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4595653A (en) 1981-06-09 1986-06-17 Lee Biomolecular Research Laboratories, Inc. Process for assaying cellular immunity
US5045320A (en) 1989-03-23 1991-09-03 Medical Biology Institute Large multivalent immunogen
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
WO1992005262A1 (en) 1990-09-14 1992-04-02 The John Hopkins University Methods and compositions for genetic therapy and potentiation of anti-tumor immunity
US5342774A (en) 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
JP3580371B2 (ja) * 1991-10-04 2004-10-20 ホワイトヘッド・インスティテュート・フォー・バイオメディカル・リサーチ サイトカインおよび抗原を用いた全身の免疫応答の調節
US5637483A (en) * 1991-10-04 1997-06-10 Whitehead Institute For Biomedical Research Irradiated tumor cell vaccine engineered to express GM-CSF
DE69533295T3 (de) * 1994-02-16 2009-07-16 The Government Of The United States Of America, As Represented By The Secretary, The Department Of Health And Human Services Melanoma-assoziierte Antigene, Epitope davon und Impstoffe gegen Melanoma
WO1995029193A2 (en) * 1994-04-22 1995-11-02 The Government Of The United States Of America Represented By The Secretary, Department Of Health And Human Services Melanoma antigens
US5759535A (en) * 1994-05-13 1998-06-02 Research Corporation Technologies, Inc. Immunotherapeutic strategies for the treatment of cancer

Also Published As

Publication number Publication date
DE69731756T2 (de) 2005-12-15
JP2016106137A (ja) 2016-06-16
JP2012001548A (ja) 2012-01-05
EP0929318A2 (en) 1999-07-21
AU3889997A (en) 1998-03-06
WO1998006746A3 (en) 1998-05-07
DE69731756D1 (de) 2004-12-30
JP2008044969A (ja) 2008-02-28
CA2263503C (en) 2012-04-10
JP2001517206A (ja) 2001-10-02
US6187306B1 (en) 2001-02-13
CA2263503A1 (en) 1998-02-19
EP0929318B1 (en) 2004-11-24
JP2014012738A (ja) 2014-01-23
WO1998006746A2 (en) 1998-02-19

Similar Documents

Publication Publication Date Title
ATE283069T1 (de) Melanomzellinien, welche immundominante melanomantigene teilen und verfahren zu deren anwendung
DE69737592D1 (de) Mittel gegen juckreiz
IT8119641A0 (it) Apparato e metodo per la determinazione ottica di giochi meccanici.
IT7920944A0 (it) Metodo, apparato e corpo disupporto di registrazioni per la registrazione ottica di informazioni.
RU93048636A (ru) 7-/замещенные/-8-/замещенные/-9-/замещенные амино/-6-диметил-6-дезокситетрациклины, промежуточные соединения, способы получения соединений, способ профилактики и лечения и фармацевтическая композиция
ATE247986T1 (de) Vorrichtung und verfahren zur aufnahme eines medizinischen instrumentes
ATE215601T1 (de) Rezeptoren der steroid/thyroid superfamilie von rezeptoren
TR199801255T2 (xx) Vitronektin resept�r antagonistleri.
DE3482076D1 (de) Plasmabearbeitungsverfahren und geraet zur anwendung dieses verfahrens.
DE69839992D1 (de) Vorbeugende- oder Heilmittel zur Behandlung von Multipler Sklerose, mit antagonistischen anti-IL6-Rezeptor Antikörpern als Wirkstoff
DE68922885D1 (de) Verfahren und Vorrichtung zur Schallbilderzeugung.
DE3482132D1 (de) Verfahren und vorrichtung zum nmr-selektiven erzeugen von bildern von chemisch verschobenen kernen.
ES2110950T3 (es) Aparato y metodo para proceso de imagenes.
DE69109213D1 (de) Verfahren und Vorrichtung zur Erzeugung von Röntgenstrahlen.
ATE38036T1 (de) Benzothiophenderivate als bronchodilatoren.
DE68910143D1 (de) Verfahren und Modulation eines optischen Strahlenbündels.
DE3781989D1 (de) Vorrichtung und verfahren zur informationskodierung eines optischen strahles.
DK0734461T3 (da) Anvendelse af et apparat til dannelse af exciteret gas
ATE199321T1 (de) Anti idiotypische antikörper gegen gonococcen und diese verwendende verfahren und zusammensetzungen.
ATE204021T1 (de) Klonierung, expression und charakterisierung einer neuen form der phosphatidylinositol-3- kinase
FI901987A0 (fi) Anordning foer blaosformning av en ihaolig kropp.
ATE181549T1 (de) Verfahren zur herstellung von (s)-3-amino-1- substituiert-pirrolidine
ATE200658T1 (de) Zeolithe und verfahren zu deren herstellung
DK0538341T3 (da) EHV-4-gycoproteinvaccine.
MX9704034A (es) Derivados y composiciones de 1,1-dioxido de 2-arilcarboniloximetil-1,2,5-tiadiazolidin-3-ona substituido y metodo de uso.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties